Among the mAbs that bind to the extracellular domain of c-MET, the fully humanized monovalent mAb onartuzumab (MetMAb, Genentech, South San Francisco, California, USA) has been evaluated in several clinical trials, but failed to show improvement when given in combination with erlotinib in patients with MET -positive NSCLC [21, 22, 99]
nejm.org SURMOUNT-1 tirzepatide trial, New England Journal of Medicine (Jastreboff et al., 2022)
It currently holds a 4.4 out of 5 rating on Trustpilot
These tests are performed using specialized laser imaging systems such as the Proveris Analytical Technologies SprayVIEW or equivalent instrumentation
doi: 10.1016/j.ajhg.2008.05.007 146
Wijesekara N, Dai FF, Hardy AB, Giglou PR, Bhattacharjee A, Koshkin V, et al